Literature DB >> 10360342

Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results.

X Du1, J L Freeman, J S Goodwin.   

Abstract

Several studies have found underutilization of radiotherapy in patients with breast cancer; but there are concerns about the completeness of various databases on radiotherapy. We used the linked Medicare-SEER (Surveillance, Epidemiology and End Results) database to compare information on receipt of radiotherapy after diagnosis of breast cancer. More than 18% of women identified by Medicare data as receiving radiotherapy were not so identified by SEER, and 7% of those identified as receiving radiotherapy by SEER were not identified by Medicare. Risk of discordance on radiotherapy information between the two data sets was especially high in women receiving breast-conserving surgery. The combined SEER-Medicare database gives a more complete picture on the use of radiotherapy. The previously reported geographic variations in the use of radiotherapy for breast cancer may be due in part to underreporting of radiotherapy in some areas.

Entities:  

Mesh:

Year:  1999        PMID: 10360342     DOI: 10.1016/s0895-4356(99)00011-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  46 in total

1.  Comparison of survival at adult versus pediatric treatment centers for rare pediatric tumors in an adolescent and young adult (AYA) population in the State of Georgia.

Authors:  Thomas Cash; Muna Qayed; Kevin C Ward; Ann C Mertens; Louis Rapkin
Journal:  Pediatr Blood Cancer       Date:  2014-11-12       Impact factor: 3.167

2.  Effect of photodynamic therapy combined with Celecoxib on expression of cyclooxygenase-2 protein in HeLa cells.

Authors:  Yuanfu Mao; Lishuang Wang; Chen Xu; Shiyu Han
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

3.  Trends in the treatment of acute myeloid leukaemia in the elderly.

Authors:  Kathleen Lang; Craig C Earle; Talia Foster; Deirdre Dixon; Renilt Van Gool; Joseph Menzin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Managed care market share and primary treatment for cancer.

Authors:  Nancy L Keating; Mary Beth Landrum; Ellen Meara; Patricia A Ganz; Edward Guadagnoli
Journal:  Health Serv Res       Date:  2006-02       Impact factor: 3.402

5.  External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.

Authors:  Xianglin L Du; Charles R Key; Lois Dickie; Ronald Darling; Jane M Geraci; Dong Zhang
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

6.  Racial disparities and trends in radiation therapy after breast-conserving surgery for early-stage breast cancer in women, 1992 to 2002.

Authors:  L Du Xianglin; Beverly J Gor
Journal:  Ethn Dis       Date:  2007       Impact factor: 1.847

7.  Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer.

Authors:  Reshma Jagsi; Paul Abrahamse; Monica Morrow; Sarah T Hawley; Jennifer J Griggs; John J Graff; Ann S Hamilton; Steven J Katz
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

8.  Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews.

Authors:  Xianglin L Du; Charles R Key; Lois Dickie; Ronald Darling; George L Delclos; Kim Waller; Dong Zhang
Journal:  J Clin Epidemiol       Date:  2005-09-30       Impact factor: 6.437

9.  Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.

Authors:  Steven T Fleming; Ann S Hamilton; Susan A Sabatino; Gretchen G Kimmick; Xiao-Cheng Wu; Jean B Owen; Bin Huang; Wenke Hwang
Journal:  Med Care       Date:  2014-09       Impact factor: 2.983

10.  Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.

Authors:  Joseph Menzin; Kathleen Lang; Craig C Earle; Alastair Glendenning
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.